Clinical Trial Center

Multiprofile Hospital for Active Treatment Puls

Stroke

Cerebral Infarction

Ischemia

Ischemic Stroke

Mycoses

Transient Ischemic Attack

Invasive Candidiasis

Respiratory Tract Infections

Candidemia

Candidiasis

EDP-938

Caspofungin

Milvexian

Rezafungin

Cidara Therapeutics

Enanta Pharmaceuticals

Janssen (J&J Innovative Medicine)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Multiprofile Hospital for Active Treatment Puls | Clinical Trial Center

Site insights

Work at this site?

Active trials

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Trial sponsors